Breast Recurrence Score Test Market size is anticipated to reach USD 20 Billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of breast recurrence score test was over USD 10 Billion. The increasing emphasis on value-based healthcare is one of the main growth drivers fueling the market. The shift towards value-based healthcare is transforming the landscape of medical practices, emphasizing the importance of outcomes that matter most to patients. In the context of breast cancer, where treatment decisions have profound implications for patients' quality of life, value-based healthcare encourages the adoption of diagnostic tools that not only improve clinical outcomes but also contribute to cost-effectiveness and resource optimization. A study published demonstrated that the use of the Oncotype DX Breast Recurrence Score Test led to a significant reduction in chemotherapy use among patients with early-stage, estrogen receptor-positive breast cancer. The study reported a 46.6% reduction in the use of chemotherapy.
The breast recurrence score test is a diagnostic tool used in the field of breast cancer management to assess the risk of recurrence in early-stage, hormone receptor-positive breast cancer patients. This test provides valuable information to help guide treatment decisions, particularly with regard to whether or not to administer chemotherapy in addition to hormonal therapy. The market for breast recurrence score testing includes competition from other genetic tests and platforms aimed at assessing breast cancer prognosis and treatment planning.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~8% |
|
Base Year Market Size (2023) |
~ USD 10 Billion |
|
Forecast Year Market Size (2036) |
~ USD 20 Billion |
|
Regional Scope |
|
Type (Oncotype, MammaPrint)
The MammaPrint segment in the breast recurrence score test market is estimated to gain the largest revenue share of 60% in the year 2036. The competitive landscape in the breast cancer diagnostic market encourages innovation and expansion. Diagnostic companies and healthcare institutions actively collaborate to ensure broader access to MammaPrint and similar tests. The market for breast cancer diagnostics is competitive, with multiple tests and providers seeking to offer their services. Competition drives innovation, leading to the development of more advanced and cost-effective tests. MammaPrint segment of the market is driven by several factors, including the increasing incidence of breast cancer, advancements in personalized medicine, regulatory support, clinical validation and research, patient-centered care, expanding clinical evidence and adoption, and a competitive landscape.
End User (Hospitals, Diagnostic Laboratories, Research Institutions)
The hospitals segment in the breast recurrence score test market is expected to garner a significant share in the year 2036. The rising incidence of breast cancer is a significant growth driver for the Hospitals segment of the market. As breast cancer becomes more prevalent, hospitals are at the forefront of diagnosing and treating patients. According to the American Cancer Society, in the United States, there were an estimated 281,550 new cases of invasive breast cancer among women in 2021. Breast cancer is the most commonly diagnosed cancer in women, with one in eight women in the United States being diagnosed in their lifetime. The increasing incidence of breast cancer means that hospitals are seeing a growing number of breast cancer patients. This drives the demand for diagnostic tests like the Breast Recurrence Score Test, which provide critical information for treatment decisions.
Our in-depth analysis of the global breast recurrence score test market includes the following segments:
|
Type |
|
|
End User |
|
APAC Market Forecast
The breast recurrence score test market in the Asia Pacific region is projected to hold the largest market share of 38% by the end of 2036. The Asia Pacific region, like many other parts of the world, is shifting towards patient-centered care, emphasizing shared decision-making and patient empowerment. The Breast Recurrence Score Test aligns with this trend by providing patients with information to actively participate in their treatment decisions. It empowers patients and their healthcare providers to make informed choices about their treatment plans, enhancing patient satisfaction and demand for tests that enable them to be active participants in their healthcare. Asia Pacific region is experiencing significant growth in the market due to factors such as the increasing incidence of breast cancer, adoption of precision medicine, regulatory support, clinical validation and research, expanding clinical evidence and adoption, and the shift towards patient-centered care.
North American Market Statistics
The breast recurrence score test market in the North America region is projected to hold the second largest share during the forecast period. The rising incidence of breast cancer is a substantial growth driver for the market in North America. Breast cancer is the most common cancer among women in the United States, and its incidence continues to increase. In the United States, it is estimated that over 281,000 new cases of invasive breast cancer were diagnosed among women in 2021. The increasing incidence of breast cancer directly drives the demand for advanced diagnostic tools like the Breast Recurrence Score Test. As more women are diagnosed with breast cancer, there is a growing need for reliable tests to guide treatment decisions.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?